Straitstimes.com header logo

Choose edition

Search

singapore

asia

world

opinion

life

business

sport

Visual

Podcasts

STClassifieds

Paid press releases

Advertise with us

FAQs

Contact us

 

Pharmaceuticals sector

The winners and losers of the weight-loss economy

Fast food chains in the US like McDonald’s are changing their menus and portion sizes in response to GLP-1 users’ changing tastes in food.
Fast food chains in the US like McDonald’s are changing their menus and portion sizes in response to GLP-1 users’ changing tastes in food.

Latest stop for tourists on South Korea’s shopping trail? The pharmacy

Foreign shoppers are increasingly turning to pharmacies with a stronger focus on clinical skincare and functional beauty.
Foreign shoppers are increasingly turning to pharmacies with a stronger focus on clinical skincare and functional beauty.

Heineken document reveals worries over weight-loss drugs and beer sales

Heineken told hospitality customers that GLP-1 drugs can reduce the desire to drink and put pressure on beer and cider sales.
Heineken told hospitality customers that GLP-1 drugs can reduce the desire to drink and put pressure on beer and cider sales.

As weight-loss drug users turn to dietary supplements, doctors and regulators raise flags

Side effects of GLP-1 drugs have caused many to turn to loosely regulated dietary supplements.
Side effects of GLP-1 drugs have caused many to turn to loosely regulated dietary supplements.

Major Novartis shareholder calls for board shake-up after drug trial setbacks

Artisan Partners, a key shareholder of Swiss drugmaker Novartis, has criticised its acquisition track record and says the board “needs to improve their oversight of acquisitions”.
Artisan Partners, a key shareholder of Swiss drugmaker Novartis, has criticised its acquisition track record and says the board “needs to improve their oversight of acquisitions”.

Novartis stock falls nearly 4% as heart-drug failure deepens setbacks

Swiss drugmaker Novartis’ latest twin disappointments follow the success of its multiple sclerosis pill remibrutinib in two late-stage trials.
Swiss drugmaker Novartis’ latest twin disappointments follow the success of its multiple sclerosis pill remibrutinib in two late-stage trials.

New Zealand approves use of party drug MDMA to treat trauma

New Zealand’s Deputy Prime Minister David Seymour said the country is committed to opening up access to “innovative treatments”.
New Zealand’s Deputy Prime Minister David Seymour said the country is committed to opening up access to “innovative treatments”.

Snoring, subways and stealth ads: How big pharma targets China's waistline

China’s rate of overweight or obese people could reach more than 65 per cent by 2030, the country’s National Health Commission has said.
China’s rate of overweight or obese people could reach more than 65 per cent by 2030, the country’s National Health Commission has said.

‘No discussions’ over AstraZeneca-Bristol Myers deal, senior source says

Reports said that the two drugmakers had held preliminary talks about a possible deal that would create a pharmaceutical behemoth with a combined value of nearly US$400 billion.
Reports said that the two drugmakers had held preliminary talks about a possible deal that would create a pharmaceutical behemoth with a combined value of nearly US$400 billion.

While You Were Sleeping: 5 stories you might have missed, Aug 3, 2026

Firefighters battle a wildfire near the Agia Paraskevi village, Greece, on Aug 2, 2026.
Firefighters battle a wildfire near the Agia Paraskevi village, Greece, on Aug 2, 2026.

E-paper

Newsletters

Podcasts

RSS Feed

About Us

Terms & Conditions

Personal Data Protection Notice

Need help? Reach us here.

Advertise with us

中文版 (beta)

Download the app

Get unlimited access to exclusive stories and incisive insights from the ST newsroom

News titles published by SPH Media

The Straits Times|The Business Times|Lianhe Zaobao|Berita Harian|Tamil Murasu|Stomp
MDDI (P) 046/10/2025. Published by SPH Media Limited, Co. Regn. No.202120748H. Copyright © 2026 SPH Media Limited. All rights reserved.